Alzamend Neuro, Inc.
ALZN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001677077
In the last 90 days, Alzamend Neuro, Inc. insiders filed 1 open-market purchase and 1 sale; 12 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding Alzamend Neuro, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 13 | 12 | −1 |
| Shares | 682.2K | 2.72M | +2.04M (+298.6%) |
| Value | $723.1K | $3.26M | +$2.54M (+351.3%) |
New holders (2)
Institutions that held Alzamend Neuro, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| KMT Wealth Management, LLC | 1,329,100 | $1.59M | 1.35% |
| IFG Advisory, LLC | 22 | $26 | 0.00% |
Sold out (3)
Institutions that held Alzamend Neuro, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Morgan Stanley | 18,000 | $19.1K |
| Clearstead Advisors, LLC | 10,000 | $10.6K |
| Citigroup Inc | 5,231 | $5.54K |